Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

am

During the first quarter of 2008 our clinical trial program expanded to nine clinical trials of which seven are being conducted by us and two are being sponsored by the U.S. National Cancer Institute ("NCI").

Clinical Trials - Actively Enrolling

During the first quarter of 2008, we continued to enroll patients in our Phase II combination REOLYSIN(R)/radiation and our three Phase I/II chemotherapeutic co-therapy clinical trials in the U.K. In the U.S., we continued to enroll patients in our Phase II sarcoma and in our Phase I/II recurrent malignant glioma clinical trials.

Clinical Trials - Expanded Enrollment

During the first quarter of 2008, we announced that we had met the initial criteria to proceed to full enrolment in our U.S. Phase II trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung.

According to the trial protocol, to proceed to full enrolment of 52 patients, we had to demonstrate that at least one patient in the first 38 patients treated experienced a complete or partial response, or stable disease for greater than six months. The third patient treated in the study was demonstrated to have stable disease by RECIST criteria for more than six months as measured by CT scan. A PET scan taken at the same time showed that any residual mass was metabolically inert.

This trial is a Phase II, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN(R) is delivered intravenously to patients at a dose of 3x1010 TCID50 for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.

Eligibl
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... N.J., Oct. 8 Managed Health Care,Associates, Inc. ... that it plans to open the 2008 MHA ... Secretary, Health and Human Services,(2001-2005), former four-term Governor ... Independent Chairman, Deloitte,Center for Health Solutions. Marking the ...
... announced today that it has entered into a ... producer of infant,formula products including the Similac(R) Advance(R) ... and ARA supplier for all of its,infant formula ... with,Abbott having the right to terminate the arrangement ...
... patients to benefit from rapid, long-lasting symptom control with ... ... fumarate -, NAPA, Calif., Oct. 8 Dey, L.P., ... the launch of Perforomist(TM),(formoterol fumarate) Inhalation Solution, which will be ...
Cached Biology Technology:MHA Announces: Tommy Thompson to be Keynote Speaker at The MHA 5th Annual Business Summit 2Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 3Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 4Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 5Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 6
(Date:4/23/2014)... the first cause of dementia and affects some 400,000 ... yet been found. One of the reasons for this ... which cause alterations in nerve transmissions and the loss ... Researchers from the Institute of Neuroscience at the Universitat ... in memory consolidation and were able to develop a ...
(Date:4/23/2014)... April 23, 2014 A biomedical engineer at the ... innovative technology to make blood transfusions safer. His work ... National Institutes of Health (NIH). , Blood transfusions ... of modern medicine,s absolute necessities. Without them, for instance, ... transfusions are perfect, however. There,s strong evidence that transfusions ...
(Date:4/23/2014)... used to read quickly. It involves visual searching ... and/ or sentences. Similarly to humans, biological systems ... genetic information. Genes that need to be read ... encoding message, the easier it will be to ... de Cincia (IGC, Portugal) and Centre for Molecular ...
Breaking Biology News(10 mins):Loss of memory in Alzheimer's mice models reversed through gene therapy 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Cell division speed influences gene architecture 2
... CAMBRIDGE, Mass. The evolution of human speech was far ... link it to a specific gene, says Robert Berwick, professor ... ideas about language in a session at the annual meeting ... Sunday, Feb. 17. The session is called Mind of a ...
... considerations and fears about global warming have helped revive ... cleanly and can be produced from plants. But ... corn-based ethanol: the more corn is used in ethanol ... partly accounts for the recent run-up in world food ...
... and closely linked social and ecological systems along our ... Guerry says can be addressed by a new approach ... Guerry will discuss the use of ecosystem services, ... marine resources in her AAAS presentation Ecosystem Services Provided ...
Cached Biology News:MIT: No easy answers in evolution of human language 2MIT: No easy answers in evolution of human language 3MIT professor to discuss future of biofuels 2Can Dungeness crab and eelgrass help improve management of our marine resources? 2
AC input: 50-60 Hz230 V...
AC input: 50-60 Hz 115-120 V...
... reagent is formulated specifically for Alkaline Phosphatase ... levels of activity for both the enzyme ... final dilution. This product has been ... the customer a longer shelf life, resistance ...
... is a valuable tool for removing SDS ... of SDS in biological samples imparts a ... complex, inhibits enzymatic activity during digestion, and ... contaminant in mass spectrometry analyses. We ...
Biology Products: